Biomarkers in connective tissue disease-associated interstitial lung disease

Seminars in Respiratory and Critical Care Medicine

Volumn 35, Issue 2, 2014, Pages 181-200

  Bonella, Francesco ^a   Costabel, Ulrich ^a  

^a RUHRLANDKLINIK   (Germany)

Author keywords

biomarkers; connective tissue disease; interstitial lung disease

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE RECEPTOR; CLARA CELL PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOKINE; ENDOTHELIAL CELL ANTIBODY; GAMMA INTERFERON; HLA DRB1 ANTIGEN; HLA DRB5 ANTIGEN; LEUKOCYTE ANTIGEN; METALLOPROTEINASE; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 2; MUCIN; PEPTIDE ANTIBODY; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ARTICLE; BLOOD LEVEL; CAUSE OF DEATH; CLARA CELL; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; IMMUNOPATHOGENESIS; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; OUTCOME ASSESSMENT; POLYMYOSITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS; COMPLICATION; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; METABOLISM; PATHOPHYSIOLOGY;

AUTOANTIBODIES; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CONNECTIVE TISSUE DISEASES; HUMANS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS;

EID: 84897058780     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1371527     Document Type: Article

References (238)

1. Olson A. L., Brown K. K., Fischer A. Connective tissue disease-associated lung disease. Immunol Allergy Clin North Am: 2012; 32 4 513 536
2. Launay D., Remy-Jardin M., Michon-Pasturel U., et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol: 2006; 33 9 1789 1801 (Pubitemid 44373213)
3. Vij R., Strek M. E. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest: 2013; 143 3 814 824
4. Gutsche M., Rosen G. D., Swigris J. J. Connective tissue disease-associated interstitial lung disease: a review. Curr Respir Care Rep: 2012; 1 224 232
5. Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet: 2012; 380 9842 689 698
6. Steen V. D., Medsger T. A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis: 2007; 66 7 940 944 (Pubitemid 46999798)
7. Tyndall A. J., Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis: 2010; 69 10 1809 1815
8. Olson A. L., Swigris J. J., Sprunger D. B., et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med: 2011; 183 3 372 378
9. Vij R., Noth I., Strek M. E. Autoimmune-featured interstitial lung disease: a distinct entity. Chest: 2011; 140 5 1292 1299
10. Mittoo S., Gelber A. C., Christopher-Stine L., Horton M. R., Lechtzin N., Danoff S. K. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med: 2009; 103 8 1152 1158
11. Centola M., Cavet G., Shen Y., et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS ONE: 2013; 8 4 e60635
12. Hirata S., Dirven L., Shen Y., et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford): 2013; 52 7 1202 1207
13. Lota H. K., Renzoni E. A. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol: 2012; 2012 121439
14. Takemoto Y., Sakatani M., Takami S., et al. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis. Thorax: 1998; 53 6 459 462 (Pubitemid 28308060)
15. Seibold M. A., Wise A. L., Speer M. C., et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med: 2011; 364 16 1503 1512
16. Ishikawa N., Hattori N., Yokoyama A., Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig: 2012; 50 1 3 13
17. Horimasu Y., Hattori N., Ishikawa N., et al. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respir Med: 2012; 106 12 1756 1764
18. Papiris S. A., Kagouridis K., Bouros D. Serologic evaluation in idiopathic interstitial pneumonias. Curr Opin Pulm Med: 2012; 18 5 433 440
19. Self S. E. Autoantibody testing for autoimmune disease. Clin Chest Med: 2010; 31 3 415 422
20. Corte T. J., Copley S. J., Desai S. R., et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J: 2012; 39 3 661 668
21. Nagai S., Handa T., Tabuena R., Kitaichi M., Izumi T. Nonspecific interstitial pneumonia: a real clinical entity? Clin Chest Med: 2004; 25 4 705 715, vi (Pubitemid 39556503)
22. Prasse A., Müller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis. Respirology: 2009; 14 6 788 795
23. Lukacs N. W., Hogaboam C., Chensue S. W., Blease K., Kunkel S. L. Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis. Chest: 2001; 120 (1, Suppl): 5S 8S (Pubitemid 32702104)
24. Ramos C., Montaño M., García-Alvarez J., et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol: 2001; 24 5 591 598 (Pubitemid 32442767)
25. Selman M., King T. E., Pardo A.; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med: 2001; 134 2 136 151 (Pubitemid 32096342)
26. Selman M., Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res: 2002; 3 3
27. Chapman H. A. Disorders of lung matrix remodeling. J Clin Invest: 2004; 113 2 148 157
28. Tzouvelekis A., Kouliatsis G., Anevlavis S., Bouros D. Serum biomarkers in interstitial lung diseases. Respir Res: 2005; 6 78
29. Hant F. N., Ludwicka-Bradley A., Wang H. J., et al. Scleroderma Lung Study Research Group. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol: 2009; 36 4 773 780
30. Assassi S., Sharif R., Lasky R. E., et al. GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther: 2010; 12 5 R166
31. Murray L. A., Rubinowitz A., Herzog E. L. Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease? Curr Opin Rheumatol: 2012; 24 6 656 662
32. Baraut J., Michel L., Verrecchia F., Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev: 2010; 10 2 65 73
33. Fertig N., Domsic R. T., Rodriguez-Reyna T., et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum: 2009; 61 7 958 965
34. Okano Y., Steen V. D., Medsger T. A. Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med: 1993; 119 10 1005 1013 (Pubitemid 23334657)
35. Mihai C., Tervaert J. W. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis: 2010; 69 2 319 324
36. Hill M. B., Phipps J. L., Cartwright R. J., Milford Ward A., Greaves M., Hughes P. Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol: 1996; 106 3 491 497 (Pubitemid 26393640)
37. Ihn H., Sato S., Fujimoto M., et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol: 2000; 119 1 203 209 (Pubitemid 30064611)
38. Odani T., Yasuda S., Ota Y., et al. Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01:05 allele in scleroderma patients with interstitial lung disease. Rheumatology (Oxford): 2012; 51 10 1765 1774
39. Delgado-Vega A., Sánchez E., Löfgren S., Castillejo- López C., Alarcón-Riquelme M. E. Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol: 2010; 22 6 698 705
40. Ohshimo S., Yokoyama A., Hattori N., Ishikawa N., Hirasawa Y., Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun: 2005; 338 4 1845 1852 (Pubitemid 41643100)
41. Seko A., Ohkura T., Ideo H., Yamashita K. Novel O-linked glycans containing 6′-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody. Glycobiology: 2012; 22 2 181 195
42. Yamane K., Ihn H., Kubo M., et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol: 2000; 27 4 930 934 (Pubitemid 30389749)
43. Yanaba K., Hasegawa M., Hamaguchi Y., Fujimoto M., Takehara K., Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol: 2003; 21 4 429 436 (Pubitemid 36950310)
44. Yanaba K., Hasegawa M., Takehara K., Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol: 2004; 31 6 1112 1120 (Pubitemid 38715886)
45. Bonella F., Volpe A., Caramaschi P., et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis: 2011; 28 1 27 33
46. Doishita S., Inokuma S., Asashima H., et al. Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases. Intern Med: 2011; 50 23 2889 2892
47. Janssen R., Kruit A., Grutters J. C., Ruven H. J., Gerritsen W. B., van den Bosch J. M. The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels. Am J Respir Cell Mol Biol: 2006; 34 4 496 499
48. Janssen R., Sato H., Grutters J. C., et al. Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest: 2003; 124 6 2119 2125 (Pubitemid 38010578)
49. Bernard A., Hermans C., Van Houte G. Transient increase of serum Clara cell protein (CC16) after exposure to smoke. Occup Environ Med: 1997; 54 1 63 65 (Pubitemid 27076896)
50. Petrek M., Hermans C., Kolek V., Fialová J., Bernard A. Clara cell protein (CC16) in serum and bronchoalveolar lavage fluid of subjects exposed to asbestos. Biomarkers: 2002; 7 1 58 67 (Pubitemid 34097610)
51. Hermans C., Petrek M., Kolek V., et al. Serum Clara cell protein (CC16), a marker of the integrity of the air-blood barrier in sarcoidosis. Eur Respir J: 2001; 18 3 507 514 (Pubitemid 32895636)
52. Kucejko W., Chyczewska E., Naumnik W., Ossolińska M. Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. Folia Histochem Cytobiol: 2009; 47 2 225 230
53. Hasegawa M., Fujimoto M., Hamaguchi Y., et al. Use of serum Clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. J Rheumatol: 2011; 38 5 877 884
54. Pastva A. M., Wright J. R., Williams K. L. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc: 2007; 4 3 252 257 (Pubitemid 47036444)
55. Takahashi H., Kuroki Y., Tanaka H., et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med: 2000; 162 1 258 263 (Pubitemid 30469830)
56. Asano Y., Ihn H., Yamane K., et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum: 2001; 44 6 1363 1369 (Pubitemid 32537535)
57. Johansen J. S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull: 2006; 53 2 172 209 (Pubitemid 43772025)
58. Korthagen N. M., van Moorsel C. H., Barlo N. P., et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med: 2011; 105 1 106 113
59. Nordenbaek C., Johansen J. S., Halberg P., et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol: 2005; 34 4 293 297 (Pubitemid 41215663)
60. Prasse A., Pechkovsky D. V., Toews G. B., et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum: 2007; 56 5 1685 1693 (Pubitemid 46764100)
61. Kodera M., Hasegawa M., Komura K., Yanaba K., Takehara K., Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum: 2005; 52 9 2889 2896 (Pubitemid 41369120)
62. Tiev K. P., Hua-Huy T., Kettaneh A., et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J: 2011; 38 6 1355 1360
63. Prasse A., Probst C., Bargagli E., et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2009; 179 8 717 723
64. Elhaj M., Charles J., Pedroza C., et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol: 2013; 40 7 1114 1120
65. Bonella F., Caramaschi P. The ambitious goal of validating prognostic biomarkers for systemic sclerosis-related interstitial lung disease. J Rheumatol: 2013; 40 7 1034 1036
66. Carulli M. T., Handler C., Coghlan J. G., Black C. M., Denton C. P. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Ann Rheum Dis: 2008; 67 1 105 109
67. Hasegawa M., Sato S., Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol: 1999; 117 1 159 165 (Pubitemid 29292792)
68. Antonelli A., Ferri C., Fallahi P., et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford): 2008; 47 1 45 49 (Pubitemid 350286260)
69. Schmidt K., Martinez-Gamboa L., Meier S., et al. Bronchoalveolar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther: 2009; 11 4 R111
70. Hasegawa M., Fujimoto M., Matsushita T., Hamaguchi Y., Takehara K., Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol: 2011; 30 2 231 237
71. Campioni D., Lo Monaco A., Lanza F., et al. CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis. Haematologica: 2008; 93 8 1233 1237
72. Song J. W., Do K. H., Jang S. J., Colby T. V., Han S., Kim D. S. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest: 2013; 143 5 1422 1429
73. Moinzadeh P., Krieg T., Hellmich M., et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol: 2011; 20 9 770 773
74. Kim W. U., Min S. Y., Cho M. L., et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther: 2005; 7 1 R71 R79
75. Andersen G. N., Nilsson K., Pourazar J., et al. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med: 2007; 101 10 2199 2206 (Pubitemid 47333670)
76. Manetti M., Guiducci S., Romano E., et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis: 2012; 71 6 1064 1072
77. Kikuchi K., Kubo M., Sato S., Fujimoto M., Tamaki K. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol: 1995; 33 6 973 978
78. Taniguchi T., Asano Y., Akamata K., et al. Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis. J Eur Acad Dermatol Venereol: 2013; 27 6 747 753
79. Oka S., Furukawa H., Shimada K., et al. Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease. BMC Immunol: 2013; 14 9
80. Tripathi S. S., Mishra V., Shukla M., et al. IL-6 receptor-mediated lung Th2 cytokine networking in silica-induced pulmonary fibrosis. Arch Toxicol: 2010; 84 12 947 955
81. Chang C. H., Hsiao C. F., Yeh Y. M., et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer: 2013; 132 9 1977 1985
82. Simeonova P. P., Toriumi W., Kommineni C., et al. Molecular regulation of IL-6 activation by asbestos in lung epithelial cells: role of reactive oxygen species. J Immunol: 1997; 159 8 3921 3928 (Pubitemid 127469648)
83. De Lauretis A., Sestini P., Pantelidis P., et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol: 2013; 40 4 435 446
84. Wuttge D. M., Wildt M., Geborek P., Wollheim F. A., Scheja A., Akesson A. Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease. Arthritis Res Ther: 2007; 9 5 R85
85. Kurasawa K., Hirose K., Sano H., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum: 2000; 43 11 2455 2463
86. Komura K., Fujimoto M., Hasegawa M., et al. Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol: 2008; 35 1 120 125
87. Truchetet M. E., Brembilla N. C., Montanari E., Allanore Y., Chizzolini C. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther: 2011; 13 5 R166
88. Martinez-Lostao L., Marzo I., Anel A., Naval J. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochem Pharmacol: 2012; 83 11 1475 1483
89. Azab N. A., Rady H. M., Marzouk S. A. Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol: 2012; 31 9 1359 1364
90. Günther A., Korfei M., Mahavadi P., von der Beck D., Ruppert C., Markart P. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev: 2012; 21 124 152 160
91. Cambrey A. D., Harrison N. K., Dawes K. E., et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol: 1994; 11 4 439 445
92. Abraham D. J., Vancheeswaran R., Dashwood M. R., et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol: 1997; 151 3 831 841 (Pubitemid 27385615)
93. Ihn H., Sato S., Fujimoto M., Takehara K., Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol: 1998; 37 11 1188 1192
94. Kuryliszyn-Moskal A., Klimiuk P. A., Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol: 2005; 24 2 111 116 (Pubitemid 40552961)
95. Vancheeswaran R., Magoulas T., Efrat G., et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol: 1994; 21 10 1838 1844 (Pubitemid 24312644)
96. Costabel U., Guzman J., Bonella F., Oshimo S. Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med: 2007; 28 5 514 524 (Pubitemid 350036962)
97. Bouros D., Wells A. U., Nicholson A. G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med: 2002; 165 12 1581 1586 (Pubitemid 34693935)
98. Wells A. U., Hansell D. M., Rubens M. B., et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med: 1994; 150 2 462 468 (Pubitemid 24252359)
99. Wells A. U., Hansell D. M., Haslam P. L., et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am J Respir Crit Care Med: 1998; 157 5, Pt 1 1474 1482
100. Behr J., Vogelmeier C., Beinert T., et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med: 1996; 154 2, Pt 1 400 406 (Pubitemid 26269110)
101. Goh N. S., Veeraraghavan S., Desai S. R., et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum: 2007; 56 6 2005 2012 (Pubitemid 47110399)
102. Tashkin D. P., Elashoff R., Clements P. J., et al. Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med: 2007; 176 10 1026 1034 (Pubitemid 350127847)
103. Strange C., Bolster M. B., Roth M. D., et al. Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med: 2008; 177 1 91 98
104. Fischer A., Meehan R. T., Feghali-Bostwick C. A., West S. G., Brown K. K. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest: 2006; 130 4 976 981 (Pubitemid 44583724)
105. Sato L. T., Kayser C., Andrade L. E. Nailfold capillaroscopy abnormalities correlate with cutaneous and visceral involvement in systemic sclerosis patients. Acta Reumatol Port: 2009; 34 (2A): 219 227
106. Bredemeier M., Xavier R. M., Capobianco K. G., et al. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol: 2004; 31 2 286 294 (Pubitemid 38160750)
107. Corrado A., Carpagnano G. E., Gaudio A., Foschino-Barbaro M. P., Cantatore F. P. Nailfold capillaroscopic findings in systemic sclerosis related lung fibrosis and in idiopathic lung fibrosis. Joint Bone Spine: 2010; 77 6 570 574
108. Douglas W. W., Tazelaar H. D., Hartman T. E., et al. Polymyositis- dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med: 2001; 164 7 1182 1185 (Pubitemid 33052247)
109. Tazelaar H. D., Viggiano R. W., Pickersgill J., Colby T. V. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis: 1990; 141 3 727 733 (Pubitemid 20109165)
110. Fathi M., Lundberg I. E., Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med: 2007; 28 4 451 458 (Pubitemid 350194727)
111. Airio A., Kautiainen H., Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol: 2006; 25 2 234 239 (Pubitemid 43372323)
112. Ponyi A., Constantin T., Balogh Z., et al. Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rheumatol: 2005; 23 1 50 56 (Pubitemid 40424758)
113. Connors G. R., Christopher-Stine L., Oddis C. V., Danoff S. K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest: 2010; 138 6 1464 1474
114. Fathi M., Vikgren J., Boijsen M., et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum: 2008; 59 5 677 685 (Pubitemid 351679543)
115. Mimori T., Nakashima R., Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep: 2012; 14 3 264 274
116. Yokoyama T., Sakamoto T., Shida N., et al. Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes. J Intensive Care Med: 2005; 20 3 160 163 (Pubitemid 43086468)
117. Suda T., Fujisawa T., Enomoto N., et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J: 2006; 28 5 1005 1012 (Pubitemid 46331972)
118. Matsushita T., Hasegawa M., Fujimoto M., et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol: 2007; 34 5 1012 1018 (Pubitemid 46774847)
119. Hamaguchi Y., Fujimoto M., Matsushita T., et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE: 2013; 8 4 e60442
120. Ghirardello A., Bassi N., Palma L., et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep: 2013; 15 6 335
121. Yoshida S., Akizuki M., Mimori T., Yamagata H., Inada S., Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum: 1983; 26 5 604 611 (Pubitemid 13090012)
122. Hirakata M., Suwa A., Nagai S., et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol: 1999; 162 4 2315 2320 (Pubitemid 29288856)
123. Sato S., Kuwana M., Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford): 2007; 46 5 842 845 (Pubitemid 47061719)
124. Stone K. B., Oddis C. V., Fertig N., et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum: 2007; 56 9 3125 3131 (Pubitemid 47502760)
125. La Corte R., Lo Mo Naco A., Locaputo A., Dolzani F., Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity: 2006; 39 3 249 253 (Pubitemid 43879038)
126. Kunimasa K., Arita M., Nakazawa T., et al. The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis. Intern Med: 2012; 51 24 3405 3410
127. Sato S., Hirakata M., Kuwana M., et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum: 2005; 52 5 1571 1576 (Pubitemid 40663949)
128. Nakashima R., Imura Y., Kobayashi S., et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford): 2010; 49 3 433 440
129. Hoshino K., Muro Y., Sugiura K., Tomita Y., Nakashima R., Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford): 2010; 49 9 1726 1733
130. Sato S., Kuwana M., Fujita T., Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol: 2013; 23 3 496 502
131. Tanizawa K., Handa T., Nakashima R., et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med: 2011; 105 9 1380 1387
132. Tanizawa K., Handa T., Nakashima R., et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med: 2013; 107 5 745 752
133. Bandoh S., Fujita J., Ohtsuki Y., et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis: 2000; 59 4 257 262 (Pubitemid 30305566)
134. Kubo M., Ihn H., Yamane K., et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford): 2000; 39 6 632 636 (Pubitemid 30459949)
135. Ohnishi H., Yokoyama A., Kondo K., et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med: 2002; 165 3 378 381 (Pubitemid 34118512)
136. Fathi M., Barbasso Helmers S., Lundberg I. E. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med: 2012; 271 6 589 597
137. Kumánovics G., Minier T., Radics J., Pálinkás L., Berki T., Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol: 2008; 26 3 414 420 (Pubitemid 352003209)
138. Gono T., Kawaguchi Y., Hara M., et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford): 2010; 49 7 1354 1360
139. Gono T., Kawaguchi Y., Ozeki E., et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol: 2011; 21 2 223 227
140. Gono T., Sato S., Kawaguchi Y., et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford): 2012; 51 9 1563 1570
141. Ihn H., Asano Y., Kubo M., et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology (Oxford): 2002; 41 11 1268 1272 (Pubitemid 35363801)
142. Satoh H., Kurishima K., Ishikawa H., Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med: 2006; 260 5 429 434 (Pubitemid 44571130)
143. Arai S., Kurasawa K., Maezawa R., Owada T., Okada H., Fukuda T. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Mod Rheumatol: 2013; 23 5 872 883
144. Zandman-Goddard G., Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev: 2007; 6 7 457 463 (Pubitemid 47079115)
145. Gono T., Kawaguchi Y., Satoh T., et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford): 2010; 49 9 1713 1719
146. Tucci M., Quatraro C., Dammacco F., Silvestris F. Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann N Y Acad Sci: 2007; 1107 184 192 (Pubitemid 47528795)
147. Wang P. Z., Guan J. L., Han X. H. The predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis/dermatomyositis [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi: 2008; 31 6 417 420
148. Krystufková O., Vallerskog T., Helmers S. B., et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis: 2009; 68 6 836 843
149. Okada M., Suzuki K., Nakanishi T., Nakashima M. Serum levels of KL-6 are positively correlated with those of CA15-3 in patients with interstitial pneumonia associated with collagen diseases. Respirology: 2006; 11 4 509 510 (Pubitemid 43824352)
150. Antoniou K. M., Margaritopoulos G., Economidou F., Siafakas N. M. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J: 2009; 33 4 882 896
151. Marie I., Hachulla E., Chérin P., et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum: 2002; 47 6 614 622 (Pubitemid 35461314)
152. Schnabel A., Reuter M., Biederer J., Richter C., Gross W. L. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum: 2003; 32 5 273 284 (Pubitemid 36459277)
153. Froidevaux-Janin S., Dudler J., Nicod L. P., Lazor R. Interstitial lung disease in rheumatoid arthritis [in French]. Rev Med Suisse: 2011; 7 318 2272 2277
154. Gizinski A. M., Mascolo M., Loucks J. L., et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol: 2009; 28 5 611 613
155. Keith R. C., Powers J. L., Redente E. F., et al. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice. Exp Lung Res: 2012; 38 2 55 66
156. Marigliano B., Soriano A., Margiotta D., Vadacca M., Afeltra A. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev: 2013; 12 11 1076 1084
157. Alexiou I., Germenis A., Koutroumpas A., Kontogianni A., Theodoridou K., Sakkas L. I. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol: 2008; 27 4 511 513
158. Mori S., Koga Y., Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med: 2012; 106 11 1591 1599
159. Aubart F., Crestani B., Nicaise-Roland P., et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol: 2011; 38 6 979 982
160. Nielen M. M., van Schaardenburg D., Reesink H. W., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum: 2004; 50 2 380 386 (Pubitemid 38198821)
161. Oliver J. E., Silman A. J. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol: 2006; 35 3 169 174 (Pubitemid 43890735)
162. Masdottir B., Jónsson T., Manfredsdottir V., Víkingsson A., Brekkan A., Valdimarsson H. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford): 2000; 39 11 1202 1205
163. Manfredsdottir V. F., Vikingsdottir T., Jonsson T., et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford): 2006; 45 6 734 740 (Pubitemid 43985343)
164. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol: 2000; 27 3 630 637 (Pubitemid 30151338)
165. Sakaida H. IgG rheumatoid factor in rheumatoid arthritis with interstitial lung disease [in Japanese]. Ryumachi: 1995; 35 4 671 677
166. Wegner N., Lundberg K., Kinloch A., et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev: 2010; 233 1 34 54
167. Sokolove J., Bromberg R., Deane K. D., et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE: 2012; 7 5 e35296
168. van de Stadt L. A., van der Horst A. R., de Koning M. H., et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis: 2011; 70 1 128 133
169. Deane K. D., Nicolls M. R. Developing better biomarkers for connective tissue disease-associated interstitial lung disease: citrullinated hsp90 autoantibodies in rheumatoid arthritis. Arthritis Rheum: 2013; 65 4 864 868
170. Klareskog L., Stolt P., Lundberg K., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum: 2006; 54 1 38 46 (Pubitemid 43122184)
171. Fischer A., Solomon J. J., du Bois R. M., et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med: 2012; 106 7 1040 1047
172. Demoruelle M. K., Deane K. Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance. Curr Rheumatol Rep: 2011; 13 5 421 430
173. Harlow L., Rosas I. O., Gochuico B. R., et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum: 2013; 65 4 869 879
174. Kahloon R. A., Xue J., Bhargava A., et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med: 2013; 187 7 768 775
175. Hassan W. U., Keaney N. P., Holland C. D., Kelly C. A. Association of HLA-DR4, protease inhibitor phenotypes and keratoconjunctivitis sicca with pulmonary abnormalities in rheumatoid arthritis. Br J Rheumatol: 1995; 34 1 37 40
176. Hillarby M. C., McMahon M. J., Grennan D. M., et al. HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol: 1993; 32 9 794 797 (Pubitemid 23267596)
177. Furukawa H., Oka S., Shimada K., et al. Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope. PLoS ONE: 2012; 7 5 e33133
178. Migita K., Nakamura T., Koga T., Eguchi K. HLA-DRB1 alleles and rheumatoid arthritis-related pulmonary fibrosis. J Rheumatol: 2010; 37 1 205 207
179. Kinoshita F., Hamano H., Harada H., et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med: 2004; 98 11 1131 1137 (Pubitemid 39317944)
180. Oyama T., Kohno N., Yokoyama A., et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung: 1997; 175 6 379 385 (Pubitemid 27431215)
181. Nakajima H., Harigai M., Hara M., et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol: 2000; 27 5 1164 1170 (Pubitemid 30262499)
182. Kobayashi J., Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest: 1995; 108 2 311 315
183. Kohno N., Kyoizumi S., Awaya Y., Fukuhara H., Yamakido M., Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest: 1989; 96 1 68 73 (Pubitemid 19176416)
184. Takamura A., Hirata S., Nagasawa H., et al. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology. Mod Rheumatol: 2013; 23 2 297 303
185. Harigai M., Takamura A., Atsumi T., et al. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs. Mod Rheumatol: 2013; 23 2 284 296
186. Gabbay E., Tarala R., Will R., et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med: 1997; 156 (2, Pt 1): 528 535 (Pubitemid 27351990)
187. Gilligan D. M., O'Connor C. M., Ward K., Moloney D., Bresnihan B., FitzGerald M. X. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. Thorax: 1990; 45 8 591 596 (Pubitemid 20270476)
188. Garcia J. G., Parhami N., Killam D., Garcia P. L., Keogh B. A. Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis. Am Rev Respir Dis: 1986; 133 3 450 454 (Pubitemid 16126280)
189. Ascherman D. P. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep: 2010; 12 5 363 369
190. Gochuico B. R., Avila N. A., Chow C. K., et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med: 2008; 168 2 159 166 (Pubitemid 351185882)
191. Park J. H., Kim D. S., Park I. N., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med: 2007; 175 7 705 711
192. Boulware D. W., Hedgpeth M. T. Lupus pneumonitis and anti-SSA(Ro) antibodies. J Rheumatol: 1989; 16 4 479 481 (Pubitemid 19149405)
193. Groen H., ter Borg E. J., Postma D. S., Wouda A. A., van der Mark T. W., Kallenberg C. G. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med: 1992; 93 6 619 627
194. Nielepkowicz-Goździńska A., Fendler W., Robak E., et al. Exhaled cytokines in systemic lupus erythematosus with lung involvement. Pol Arch Med Wewn: 2013; 123 4 141 148
195. Szekanecz E., Szucs G., Szekanecz Z., et al. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun: 2008; 31 4 372 376
196. Yücel A. E., Calguneri M., Ruacan S. False positive pleural biopsy and high CA125 levels in serum and pleural effusion in systemic lupus erythematosus. Clin Rheumatol: 1996; 15 3 295 297 (Pubitemid 26186510)
197. Takeda N., Ihn H., Teramoto S. Markedly increased levels of IL-6 and CA125 in pleural fluid of an elderly person with overlap syndrome of systemic sclerosis and systemic lupus erythematosus. Age Ageing: 2001; 30 2 171 (Pubitemid 32492616)
198. Yang Z., Liang Y., Li C., Zhong R. Serum CA125 elevation is independently associated with serositis in SLE patients. Clin Exp Rheumatol: 2012; 30 1 93 98
199. Yazisiz V., Arslan G., Ozbudak I. H., et al. Lung involvement in patients with primary Sjögren's syndrome: what are the predictors? Rheumatol Int: 2010; 30 10 1317 1324
200. Yazisiz V., Avci A. B., Erbasan F., KiriŚ E., Terzioǧlu E. Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sjögren's syndrome: a retrospective analysis. Rheumatol Int: 2009; 29 4 403 409
201. Deheinzelin D., Capelozzi V. L., Kairalla R. A., Barbas Filho J. V., Saldiva P. H., de Carvalho C. R. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med: 1996; 154 3, Pt 1 794 799 (Pubitemid 26327307)
202. Ito I., Nagai S., Kitaichi M., et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med: 2005; 171 6 632 638 (Pubitemid 40365420)
203. Parambil J. G., Myers J. L., Lindell R. M., Matteson E. L., Ryu J. H. Interstitial lung disease in primary Sjögren syndrome. Chest: 2006; 130 5 1489 1495 (Pubitemid 44786744)
204. Sarkar P. K., Patel N., Furie R. A., Talwar A. Pulmonary manifestations of primary Sjögren's syndrome. Indian J Chest Dis Allied Sci: 2009; 51 2 93 101
205. Davidson B. K., Kelly C. A., Griffiths I. D. Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome. Ann Rheum Dis: 2000; 59 9 709 712
206. Takada K., Takiguchi M., Konno A., Inaba M. Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome. J Biol Chem: 2005; 280 5 3982 3988 (Pubitemid 40223867)
207. Goëb V., Salle V., Duhaut P., et al. Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome. Clin Exp Immunol: 2007; 148 2 281 287 (Pubitemid 46587585)
208. Kovács L., Fehér E., Bodnár I., et al. Demonstration of autoantibody binding to muscarinic acetylcholine receptors in the salivary gland in primary Sjögren's syndrome. Clin Immunol: 2008; 128 2 269 276
209. Shen L., Suresh L., Lindemann M., et al. Novel autoantibodies in Sjogren's syndrome. Clin Immunol: 2012; 145 3 251 255
210. Pertovaara M., Bootorabi F., Kuuslahti M., et al. Carbonic anhydrase autoantibodies and sicca symptoms in primary Sjögren syndrome. Clin Exp Rheumatol: 2012; 30 3 456 457
211. Delaleu N., Immervoll H., Cornelius J., Jonsson R. Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther: 2008; 10 1 R22
212. Wallaert B., Hatron P. Y., Grosbois J. M., Tonnel A. B., Devulder B., Voisin C. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis: 1986; 133 4 574 580 (Pubitemid 16127240)
213. Hatron P. Y., Wallaert B., Gosset D., et al. Subclinical lung inflammation in primary Sjögren's syndrome. Relationship between bronchoalveolar lavage cellular analysis findings and characteristics of the disease. Arthritis Rheum: 1987; 30 11 1226 1231 (Pubitemid 18009286)
214. Wallaert B., Prin L., Hatron P. Y., Ramon P., Tonnel A. B., Voisin C. Lymphocyte subpopulations in bronchoalveolar lavage in Sjögren's syndrome. Evidence for an expansion of cytotoxic/suppressor subset in patients with alveolar neutrophilia. Chest: 1987; 92 6 1025 1031 (Pubitemid 18026541)
215. Hajas A., Barath S., Szodoray P., et al. Derailed B cell homeostasis in patients with mixed connective tissue disease. Hum Immunol: 2013; 74 7 833 841
216. Prakash U. B. Lungs in mixed connective tissue disease. J Thorac Imaging: 1992; 7 2 55 61
217. Bodolay E., Szekanecz Z., Dévényi K., et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford): 2005; 44 5 656 661 (Pubitemid 41487239)
218. Szodoray P., Hajas A., Kardos L., et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus: 2012; 21 13 1412 1422
219. Hajas A., Szodoray P., Nakken B., et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol: 2013; 40 7 1134 1142
220. Ferreira J. P., Almeida I., Marinho A., Cerveira C., Vasconcelos C. Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol: 2012; 2012 415272
221. Ferreira R., Barreto M., Santos E., et al. Heritable factors shape natural human IgM reactivity to Ro60/SS-A and may predispose for SLE-associated IgG anti-Ro and anti-La autoantibody production. J Autoimmun: 2005; 25 2 155 163 (Pubitemid 41608560)
222. Satoh M., Hirayoshi K., Yokota S., Hosokawa N., Nagata K. Intracellular interaction of collagen-specific stress protein HSP47 with newly synthesized procollagen. J Cell Biol: 1996; 133 2 469 483 (Pubitemid 26132541)
223. Yokota S., Kubota H., Matsuoka Y., et al. Prevalence of HSP47 antigen and autoantibodies to HSP47 in the sera of patients with mixed connective tissue disease. Biochem Biophys Res Commun: 2003; 303 2 413 418 (Pubitemid 36349185)
224. Kakugawa T., Yokota S., Mukae H., et al. High serum concentrations of autoantibodies to HSP47 in nonspecific interstitial pneumonia compared with idiopathic pulmonary fibrosis. BMC Pulm Med: 2008; 8 23
225. Mosca M., Tani C., Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol: 2007; 21 6 1011 1023 (Pubitemid 350199261)
226. Lunardi F., Balestro E., Nordio B., et al. Undifferentiated connective tissue disease presenting with prevalent interstitial lung disease: case report and review of literature. Diagn Pathol: 2011; 6 50
227. Mosca M., Neri R., Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol: 1999; 17 5 615 620 (Pubitemid 29454836)
228. Mosca M., Tani C., Neri C., Baldini C., Bombardieri S. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev: 2006; 6 1 1 4 (Pubitemid 44724957)
229. Kinder B. W., Collard H. R., Koth L., et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med: 2007; 176 7 691 697 (Pubitemid 47503077)
230. Suda T., Kono M., Nakamura Y., et al. Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respir Med: 2010; 104 10 1527 1534
231. Romagnoli M., Gurioli C., Casoni G., Poletti V. Surgical lung biopsy in the diagnosis of idiopathic NSIP: do we always need it in the initial approach? Am J Respir Crit Care Med: 2009; 179 11 1071, author reply 1071-1072
232. Sato S., Nagaoka T., Hasegawa M., Nishijima C., Takehara K. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology: 2000; 200 3 196 201 (Pubitemid 30265302)
233. Antonelli A., Fallahi P., Ferrari S. M., et al. Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2. J Rheumatol: 2012; 39 5 979 985
234. Buttmann M., Merzyn C., Hofstetter H. H., Rieckmann P. TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol: 2007; 190 1-2 170 176 (Pubitemid 47625614)
235. Gourh P., Arnett F. C., Assassi S., et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther: 2009; 11 5 R147
236. Sato S., Nagaoka T., Hasegawa M., et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol: 2000; 27 1 149 154 (Pubitemid 30058642)
237. Muangchan C., Harding S., Khimdas S., Bonner A., Baron M., Pope J.; Canadian Scleroderma Research group. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken): 2012; 64 9 1405 1414
238. Iwata Y., Yoshizaki A., Ogawa F., et al. Increased serum pentraxin 3 in patients with systemic sclerosis. J Rheumatol: 2009; 36 5 976 983